The Pharma Timeline: Why a Plant Takes 3 to 7 Years

Turning a pharmaceutical manufacturing facility from vision to a running plant typically takes three to seven years. Design, construction, and startup all fight the same clock: get therapies to patients without skipping the work that keeps the plant compliant.

Water, utilities, cleanrooms, and qualification are often the parts that decide whether a project lands on the short end of that range or the long one. This is a field guide for the people who live inside those schedules.

Typical timeline

Design (6 to 18 months)

Conceptual design and feasibility: 2 to 4 months. Detailed engineering — process flow, equipment layout, GMP compliance — 4 to 12 months. The output is blueprints, user requirement specifications, and regulatory submissions.

Construction (18 to 36 months)

Site preparation and foundation: 3 to 6 months. Building shell and cleanroom installation: 6 to 12 months. Equipment installation: 6 to 18 months. The outcome is a built facility ready for qualification.

Startup and qualification (12 to 24 months)

IQ and OQ: 6 to 12 months. PQ and process validation: 6 to 12 months. Regulatory approval and commissioning: 3 to 6 months, depending on the agency. Then the facility can produce GMP product.

Small or simpler plants often land around 3 to 4 years. Large or complex plants often take 5 to 7.

What moves the schedule

Regulatory load. GMP documentation and inspection findings can add 6 to 12 months when approvals lag, especially on biologics.

Scale and complexity. A 200,000 square foot plant, or one running cell therapy instead of tablets, adds equipment and validation steps that routinely cost 1 to 2 extra years.

Technology choices. Modular or prefabricated design can cut construction by 6 to 18 months. Novel systems, including some single-use trains, can add startup time while the validation story is written.

Site and permits. Zoning, environmental review, and brownfield prep can add 3 to 12 months. Urban sites are usually slower than rural ones.

Supply chain and labor. Stainless, long-lead equipment, and people who have actually commissioned GMP plants still move the date.

Money and alignment. Late funding or a late change in scope can stall design or construction for months or years.

Execution strategy. Fast-track (overlapping design and construction) can save 6 to 12 months and raise rework risk. Sequential is slower and safer.

Faster vs slower facility types

Often faster (about 3 to 4 years): small-molecule oral solids, and some modular or single-use facilities. Simpler processes, more standard equipment, less sterility burden.

Often slower (about 5 to 8 years): biologics with Class A space and living cells; cell and gene therapy with small-batch suites and still-moving guidance.

Hybrids that mix R&D and manufacturing often land in the 4 to 6 year band.

The takeaway

The range is real. Modularity and fast-tracking show up on the short projects. GMP rigor still sets the floor. If you have lived a standout speed-up or a painful delay, that is exactly the kind of story this show exists to record.

Originally published on LinkedIn in March 2025 and adapted here for the Modern BioPharma Podcast.